Delivery Order SPE2DB24D2010-SPE2DB25FAAVN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,004.33 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitive award, issued on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a firm fixed-price transaction with no set-aside designation. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters and a major...
- The Defense Logistics Agency awarded a delivery order valued at $7,547.69 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with an ultimate completion date of July 31, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across...
- The Defense Logistics Agency awarded a delivery order valued at $1,879.98 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract was awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, and represents a firm fixed price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $6,266.60 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL quantities. The contract is competitively awarded with no set-aside designation and employs firm fixed pricing. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,947.43 for Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with an ultimate completion date of August 1, 2025. This firm fixed price contract, awarded on July 31, 2025, represents a competitive award with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $45,468.54 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials, with an ultimate completion date of August 13, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $30,496.07 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed price contract with an ultimate completion date of August 8, 2025, and represents a competitively awarded, non-set-aside procurement. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a $27,077.48 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery order represents a single-transaction pharmaceutical procurement under...
- The Defense Logistics Agency awarded a $44,381.09 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion targeted for August 12, 2025. This competitive, non-set-aside award reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.96 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL quantities. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025. This delivery order represents a single transaction...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAVNDelivery Order
The Defense Logistics Agency awarded a $36,539.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with an ultimate completion date of August 18, 2025. This competitively awarded contract without set-aside designation reflects DLA's pharmaceutical procurement needs to support military healthcare operations. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, with performance occurring at its corporate office location. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The overarching IDC functions as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. The contract structure demonstrates DLA's strategy to maintain flexible, long-term relationships with qualified pharmaceutical vendors capable of fulfilling diverse medical supply requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.5k | 8/15/25 |